Drug Trial Radar · NCT04760626
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,085
Actual
Start
Mar 1, 2021
Primary completion
Aug 12, 2022
Study completion Aug 29, 2022
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Feb 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App. The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Conditions
- Diabetes Mellitus, Type 2
Interventions
Insulin icodecDrug
Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
Insulin Glargine 100U/mLDrug
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Insulin DegludecDrug
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Insulin Glargine 300U/mLDrug
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (week 0), week 52
Locations
311 sites in 10 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Lakeview Clinical Research, LLC
Guntersville, Alabama
Pri Med Grp dba/Gil Ctr Fam
Gilbert, Arizona
Lynn Institute of the Ozarks
Little Rock, Arkansas
Anaheim Clinical Trials, LLC
Anaheim, California
Advanced Clinical Research/Rancho Paseo Medical Group
Banning, California
American Clinical Trials
Buena Park, California
San Fernando Valley Hlth Inst, LLC
Canoga Park, California
Med Center Medical Clinic
Carmichael, California
Headlands Research California, LLC
Escondido, California
Valley Research
Fresno, California
Advanced Investigative Medicine, Inc.
Hawthorne, California
Diabetes/Lipid Mgmt & Res Ctr
Huntington Beach, California
Altman Clin & Trans Res Inst
La Jolla, California
Scripps Whittier Diabetes Inst
La Jolla, California
First Valley Medical Group
Lancaster, California
Torrance Clin Res Inst, Inc.
Lomita, California
Adventist Health White Memorial
Los Angeles, California
Providence Clinical Research
North Hollywood, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Clinical Trials Research_Sacramento
Sacramento, California
San Diego Family Care
San Diego, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
Handelsman Yehuda
Tarzana, California
Diabetes Research Center
Tustin, California
Coastal Metabolic Research Center
Ventura, California
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado
Chase Medical Research LLC
Waterbury, Connecticut
MedStar Diabetes Institute
Washington D.C., District of Columbia
Clinical Res Of W Florida Inc
Clearwater, Florida
Revival Research
Doral, Florida
Est Cst Inst for Rsrch,Jksnvil
Jacksonville, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
University Of Miami
Miami, Florida
Adult Medicine of Lake County, Inc
Mt. Dora, Florida
Suncoast Clin Res Port Richey
New Port Richey, Florida
Florida Institute for Clinical research
Orlando, Florida
Palm Harbor Medical Associates
Palm Harbor, Florida
Showing 40 of 311 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.